Evidence map›Paper›PMID 36670352›Full record

Observational studyBMC infectious diseases2023

Benchmarking of two bioinformatic workflows for the analysis of whole-genome sequenced Staphylococcus aureus collected from patients with suspected sepsis.

Mahnaz Irani Shemirani, Diana Tilevik, Andreas Tilevik, Sanja Jurcevic, Dimitrios Arnellos, Helena Enroth, Anna-Karin Pernestig

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in BMC infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Mahnaz Irani ShemiraniDepartment of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Diana TilevikSchool of Bioscience, Systems Biology Research Centre, Infection Biology, University of Skövde, Skövde, Sweden.
Andreas TilevikSchool of Bioscience, Systems Biology Research Centre, Infection Biology, University of Skövde, Skövde, Sweden.
Sanja JurcevicSchool of Bioscience, Systems Biology Research Centre, Infection Biology, University of Skövde, Skövde, Sweden.
Dimitrios Arnellos1928 Diagnostics, Gothenburg, Sweden.
Helena EnrothSchool of Bioscience, Systems Biology Research Centre, Infection Biology, University of Skövde, Skövde, Sweden.
Anna-Karin PernestigSchool of Bioscience, Systems Biology Research Centre, Infection Biology, University of Skövde, Skövde, Sweden. anna-karin.pernestig@his.se.
University of Skövde · SE1928 Diagnostics (Sweden) · SEUniversity of Gothenburg · SE

Funding

Swedish Knowledge Foundation Associate Senior Lecturer in Systems biology, grant no. 2017/14Swedish Knowledge Foundation BioMine grant no.206/0330
6 · The paper itself

Abstract

backgroundThe rapidly growing area of sequencing technologies, and more specifically bacterial whole-genome sequencing, could offer applications in clinical microbiology, including species identification of bacteria, prediction of genetic antibiotic susceptibility and virulence genes simultaneously. To accomplish the aforementioned points, the commercial cloud-based platform, 1928 platform (1928 Diagnostics, Gothenburg, Sweden) was benchmarked against an in-house developed bioinformatic pipeline as well as to reference methods in the clinical laboratory.

methodsWhole-genome sequencing data retrieved from 264 Staphylococcus aureus isolates using the Illumina HiSeq X next-generation sequencing technology was used. The S. aureus isolates were collected during a prospective observational study of community-onset severe sepsis and septic shock in adults at Skaraborg Hospital, in the western region of Sweden. The collected isolates were characterized according to accredited laboratory methods i.e., species identification by MALDI-TOF MS analysis and phenotypic antibiotic susceptibility testing (AST) by following the EUCAST guidelines. Concordance between laboratory methods and bioinformatic tools, as well as concordance between the bioinformatic tools was assessed by calculating the percent of agreement.

resultsThere was an overall high agreement between predicted genotypic AST and phenotypic AST results, 98.0% (989/1006, 95% CI 97.3-99.0). Nevertheless, the 1928 platform delivered predicted genotypic AST results with lower very major error rates but somewhat higher major error rates compared to the in-house pipeline. There were differences in processing times i.e., minutes versus hours, where the 1928 platform delivered the results faster. Furthermore, the bioinformatic workflows showed overall 99.4% (1267/1275, 95% CI 98.7-99.7) agreement in genetic prediction of the virulence gene characteristics and overall 97.9% (231/236, 95% CI 95.0-99.2%) agreement in predicting the sequence types (ST) of the S. aureus isolates.

conclusionsAltogether, the benchmarking disclosed that both bioinformatic workflows are able to deliver results with high accuracy aiding diagnostics of severe infections caused by S. aureus. It also illustrates the need of international agreement on quality control and metrics to facilitate standardization of analytical approaches for whole-genome sequencing based predictions.

Indexed as

SepsisStaphylococcal InfectionsAdultAnti-Bacterial AgentsBacteriaBenchmarkingComputational BiologyGenome, BacterialHumansMicrobial Sensitivity TestsStaphylococcus aureusWorkflowAnti-Bacterial AgentsAntimicrobial susceptibilityBenchmarkingClinical microbiologyIllumina sequencingS. aureusSpecies identificationVirulence genesWhole-genome sequencing

Identifiers

PMID36670352
PMCPMC9863170
OpenAlexW4317545891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.